XOMA Corp Operating Income Over Time
| XOMA Stock | USD 27.04 1.72 6.79% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out XOMA Corp Performance and XOMA Corp Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XOMA Corp. Anticipated expansion of XOMA directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive XOMA Corp assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.48) | Earnings Share 0.75 | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets |
XOMA Corp's market price often diverges from its book value, the accounting figure shown on XOMA's balance sheet. Smart investors calculate XOMA Corp's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since XOMA Corp's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between XOMA Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if XOMA Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XOMA Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare XOMA Corp and related stocks such as Galectin Therapeutics, IMAB Old, and Benitec Biopharma Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GALT | (170 K) | (10.4 M) | (9.9 M) | (12.1 M) | (15.4 M) | (20.1 M) | (21.5 M) | (16.2 M) | (13.6 M) | (13.4 M) | (23.4 M) | (30.2 M) | (38.4 M) | (38.1 M) | (42.4 M) | (38.2 M) | (36.3 M) |
| BNTC | (8.2 M) | (8.2 M) | (8.2 M) | (14.4 M) | (13.3 M) | (25 M) | (15.9 M) | (8.6 M) | 2 M | (8.3 M) | (13.6 M) | (17.9 M) | (19.1 M) | (22.6 M) | (41.8 M) | (37.6 M) | (35.7 M) |
| RCKT | (5.8 M) | (5.8 M) | (5.8 M) | (6.7 M) | (7.7 M) | (20.4 M) | (41.9 M) | (26.7 M) | (71.2 M) | (76.2 M) | (136 M) | (167.2 M) | (224.3 M) | (259.7 M) | (273.2 M) | (245.9 M) | (233.6 M) |
| SLDB | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (25.6 M) | (54.9 M) | (75.7 M) | (119.3 M) | (86.5 M) | (72.3 M) | (106.5 M) | (104.3 M) | (129.7 M) | (116.8 M) | (122.6 M) |
| QSI | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.7 M) | (96.9 M) | (123.8 M) | (111.2 M) | (108.6 M) | (97.7 M) | (102.6 M) |
| DSGN | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (8.6 M) | (35.8 M) | (67.6 M) | (78.2 M) | (62.4 M) | (56.1 M) | (59 M) |
| AURA | (24.1 M) | (24.1 M) | (24.1 M) | (24.1 M) | (24.1 M) | (24.1 M) | (24.1 M) | (24.1 M) | (24.1 M) | (24.1 M) | (22.2 M) | (35.2 M) | (60.3 M) | (85 M) | (96.1 M) | (86.5 M) | (82.2 M) |
| AUTL | (57.5 M) | (57.5 M) | (57.5 M) | (57.5 M) | (57.5 M) | (8.1 M) | (14.4 M) | (23.4 M) | (57.5 M) | (247.6 M) | (303.1 M) | (140.4 M) | (142.9 M) | (179.7 M) | (241.4 M) | (217.3 M) | (206.4 M) |
| DMAC | (603.4 K) | (6.7 M) | (10.1 M) | (7.4 M) | (4.8 M) | (1.3 M) | (2.5 M) | (4.5 M) | (6.8 M) | (11.6 M) | (12.7 M) | (13.6 M) | (14 M) | (21.3 M) | (26.7 M) | (24 M) | (22.8 M) |
XOMA Corp and related stocks such as Galectin Therapeutics, IMAB Old, and Benitec Biopharma Operating Income description
Operating Income is the amount of profit realized from XOMA Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of XOMA Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| XOMA Corp | XOMA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2200 Powell Street, |
| Exchange | NASDAQ Exchange |
USD 27.04
Check out XOMA Corp Performance and XOMA Corp Correlation. For information on how to trade XOMA Stock refer to our How to Trade XOMA Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
XOMA Corp technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.